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Attention-deficit hyperactivity disorder (ADHD)
is characterized by inattention, hyperactivity, and
impulsivity.[2] Globally, ADHD affects approx-
imately 5–10% of children[3] and persists into
adolescence in up to 85% of affected individuals.[4]
Psychostimulants, such as methylphenidate and
amfetamine, are the mainstay of treatment in
ADHD.[2]
A patch that delivers methylphenidate trans-
dermally (methylphenidate transdermal system;
Daytrana) has been developed for the treatment
of ADHD. The patch comprises a backing layer,
an adhesive formulation that incorporates me-
thylphenidate and uses DOT Matrix technol-
ogy, and a protective liner, which is removed
prior to application.[5] The features and proper-
ties of methylphenidate transdermal system (in-
cluding available patch sizes and the nominal
methylphenidate dose delivered by each patch
size) are shown in table I. Once applied to the skin,
methylphenidate transdermal system releases me-
thylphenidate continuously. A potential advant-
age of this patch technology is that it allows the
duration of the effect to be tailored to the indi-
vidual by varying the duration of the application
(‘wear time’).[6]
Methylphenidate transdermal system is ap-
proved in the US for the treatment of ADHD,[5]
and its use in children aged 6–12 years with
ADHD has been reviewed previously.[7] This
profile report examines the use of methylpheni-
date transdermal system in adolescents aged
13–17 years with ADHD.
Adolescents aged 13–17 years with ADHD
were randomized to receive methylphenidate
transdermal system or placebo transdermal sys-
tem in a double-blind, multicenter, 7-week trial
(core trial).[8] During a 5-week dose-optimization
period, patients were titrated to their optimal
methylphenidate transdermal system dosage (10,
15, 20, or 30mg); the dose-optimization period
was followed by a 2-week maintenance period,
during which patients continued treatment at
their optimal dosage. Patches were applied to the
hip each morning and worn for 9 hours per day.[8]
Following the core trial, eligible patients could
receive longer-term therapy with methylphenidate
transdermal system 10–30mg in a noncomparative
extension study of »6 months duration.[9]
According to the results of the core trial, me-
thylphenidate transdermal system 10–30mg was
effective in adolescents aged 13–17 years with
ADHD.[8] The mean ADHD-Rating Scale-IV
(ADHD-RS-IV) total score (primary endpoint)
decreased to a significantly (p < 0.001) greater
extent in adolescents receiving methylphenidate
transdermal system (n = 143) than in those re-
ceiving placebo transdermal system (n = 72), with
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a least squares mean between-group difference of
-9.96 (95% CI -13.39, -6.53). The mean ADHD-
RS-IV total score at study end was 17.7 in me-
thylphenidate transdermal system recipients and
27.7 in placebo transdermal system recipients; the
mean baseline scores were 36.4 and 36.6 in the
corresponding treatment groups.[8]
In the extension study, methylphenidate trans-
dermal system recipients experienced a signif-
icant (p < 0.001) reduction from the start of the
core trial in the mean ADHD-RS-IV total score
of 23.0.[9]
Methylphenidate transdermal system was
generally well tolerated in adolescents with
ADHD. The vast majority of treatment-emergent
adverse events were of mild to moderate severity
in both the short-term core trial[8] and the longer-
term extension study.[9] In the core trial, the most
frequently reported treatment-emergent adverse
events (occurring in ‡5% of methylphenidate
transdermal system recipients and in numerically
more methylphenidate transdermal system than
placebo transdermal system recipients) included
decreased appetite, irritability, upper respiratory
tract infection, nausea, insomnia, dizziness, and
decreased weight.[8] A similar tolerability profile
was seen during the extension study.[9]
In the core trial, most of the skin reactions to
methylphenidate transdermal system comprised
mild erythema, and adherence of the methyl-
phenidate transdermal system patch to the skin
was rated at ‡90% overall.[8] Changes in the blood
pressure and pulse rate observed in the core[8] and
extension[9] studies were typical of those seen in
patients receiving stimulants.
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Table I. Features and properties of methylphenidate transdermal
system (Daytrana)[1]
Featured indication
Treatment of attention-deficit hyperactivity disorder (ADHD) in
adolescents aged 13–17 years
Mechanism of action
Possibly blocks dopamine and norepinephrine (noradrenaline)
reuptake into the presynaptic neuron, increasing their release into
the extraneuronal space
Dosage and administration






Route of administration Transdermal
Frequency of administration Once daily
Steady-state pharmacokinetics of d-methylphenidate following
repeat application of methylphenidate transdermal system













Treatment-emergent adverse events occurring in ‡5% of
adolescents with ADHD receiving methylphenidate
transdermal system
Decreased appetite, headache, irritability, upper respiratory tract
infection, nausea, insomnia, dizziness, decreased weight,
nasopharyngitis
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